TuHURA draws two more tranches on $50 million Parkview credit line

TuHURA Biosciences, Inc. took two additional draws in August 2026 under its revolving credit facility with Parkview Holdings One LLC, according to a pair of Form 8-K filings.

The underlying facility dates to April 21, 2026, when TuHURA Biosciences entered into a Loan Agreement with Parkview Holdings One LLC as lender, establishing a revolving credit facility maturing on April 21, 2031, with maximum loan availability of $50 million.¹

On August 7, 2026, the company borrowed $650,000 under the facility and said it expected to use the funds for general corporate purposes.¹ That filing was signed August 13, 2026.

A second draw followed on August 20, 2026, when TuHURA received and borrowed an additional $650,000 under the revolving credit facility, again stating the funds were expected to be used for general corporate purposes.²

Separately, an August 18, 2026 8-K disclosed developments tied to the same loan arrangement. Under a Fee Letter also dated April 21, 2026, the company had agreed to issue an aggregate of 1,878,287 shares of common stock to Parkview, subject to stockholder approval.³ That approval came through at TuHURA's 2026 Annual Meeting, held August 18, 2026, where stockholders approved the Nasdaq Proposal covering issuance of the 1,878,287 shares by a majority of votes cast, with 28,128,581 votes for, 517,896 against, and 83,855 abstaining, against 14,303,692 broker non-votes.³ As a result, the company said it will issue the Loan Fee Shares to Parkview.³

The same meeting also re-elected all six director nominees, ratified Cherry Bekaert LLP as auditor for fiscal 2026, and saw stockholders favor a three-year frequency for future say-on-pay votes, per the filing's reported vote tallies.